OA11569A - Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. - Google Patents

Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. Download PDF

Info

Publication number
OA11569A
OA11569A OA1200000346A OA1200000346A OA11569A OA 11569 A OA11569 A OA 11569A OA 1200000346 A OA1200000346 A OA 1200000346A OA 1200000346 A OA1200000346 A OA 1200000346A OA 11569 A OA11569 A OA 11569A
Authority
OA
OAPI
Prior art keywords
oxo
pyridin
ethyl
phenyl
compound
Prior art date
Application number
OA1200000346A
Other languages
English (en)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11569A publication Critical patent/OA11569A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
OA1200000346A 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. OA11569A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
OA11569A true OA11569A (en) 2004-07-01

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000346A OA11569A (en) 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.

Country Status (29)

Country Link
EP (1) EP1085867A1 (ja)
JP (1) JP2002518328A (ja)
KR (1) KR20010052817A (ja)
CN (1) CN1305378A (ja)
AP (1) AP9901581A0 (ja)
AR (1) AR018868A1 (ja)
AU (1) AU3342099A (ja)
BG (1) BG105128A (ja)
BR (1) BR9911357A (ja)
CA (1) CA2335112A1 (ja)
CO (1) CO5070586A1 (ja)
EA (1) EA200001189A1 (ja)
GT (1) GT199900083A (ja)
HR (1) HRP20000857A2 (ja)
HU (1) HUP0102395A2 (ja)
ID (1) ID26726A (ja)
IL (1) IL139587A0 (ja)
IS (1) IS5727A (ja)
MA (1) MA26648A1 (ja)
NO (1) NO20006381D0 (ja)
OA (1) OA11569A (ja)
PA (1) PA8472101A1 (ja)
PE (1) PE20000633A1 (ja)
PL (1) PL345064A1 (ja)
SK (1) SK18902000A3 (ja)
TN (1) TNSN99118A1 (ja)
UY (1) UY25557A1 (ja)
WO (1) WO1999065488A1 (ja)
ZA (1) ZA993973B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
DK1460969T3 (da) * 2001-11-29 2008-09-01 Gtx Inc Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AP9901581A0 (en) 1999-06-30
CN1305378A (zh) 2001-07-25
EP1085867A1 (en) 2001-03-28
CO5070586A1 (es) 2001-08-28
BR9911357A (pt) 2001-03-13
HUP0102395A2 (hu) 2001-11-28
AR018868A1 (es) 2001-12-12
AU3342099A (en) 2000-01-05
ID26726A (id) 2001-02-01
PE20000633A1 (es) 2000-07-26
HRP20000857A2 (en) 2001-10-31
IL139587A0 (en) 2002-02-10
UY25557A1 (es) 2001-01-31
EA200001189A1 (ru) 2001-06-25
NO20006381L (no) 2000-12-14
PL345064A1 (en) 2001-11-19
CA2335112A1 (en) 1999-12-23
GT199900083A (es) 2000-12-05
PA8472101A1 (es) 2000-09-29
JP2002518328A (ja) 2002-06-25
TNSN99118A1 (fr) 2005-11-10
SK18902000A3 (sk) 2001-12-03
KR20010052817A (ko) 2001-06-25
WO1999065488A1 (en) 1999-12-23
BG105128A (en) 2001-11-30
IS5727A (is) 2000-11-24
ZA993973B (en) 2000-12-15
MA26648A1 (fr) 2004-12-20
NO20006381D0 (no) 2000-12-14

Similar Documents

Publication Publication Date Title
EP1414486B1 (en) Use of glp-2 in combination with another therapeutic agent in bone-related disorders
ES2312169T3 (es) Terapia combinada para osteoporosis.
US7632813B2 (en) Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
JP2003528135A (ja) 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
JPH11180926A (ja) 骨粗しょう症用化合物
JP2000514840A (ja) 成長ホルモン分泌促進物質としての置換ジペプチドの酒石酸塩
KR20140084303A (ko) 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
HRP980356A2 (en) Prostaglandin agonists
US20050065133A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist
US20050065180A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue
OA11569A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.
AU3725999A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
OA11505A (en) Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty.
EP1490055A1 (en) Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
CZ20004680A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
EP0966968B1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
MXPA00012628A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CZ20004679A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012727A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
EA008927B1 (ru) Применение производных 2h-[1,3]оксазино[3,2-a]индола для лечения невропатической боли
MXPA00012728A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
MXPA99005564A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2